Kyorin Pharma To Shut Down US Subsidiary ActivX

End Of Line For 2004 Acquisition

Kyorin Pharma is to end operations at its US subsidiary ActivX 18 years since its acquisition. Although the California firm’s kinase-probing technology has contributed to Kyorin’s R&D, the Japanese firm acknowledged limits to future applicability in the development of candidate compounds.

Kyorin decided to shut down its subsidiary ActivX
ActivX to end operations by 31 March 2023 • Source: Shutterstock

More from Strategy

More from Business